B Davidson

Summary

Affiliation: University of Oslo
Country: Norway

Publications

  1. ncbi Gene expression signatures differentiate uterine endometrial stromal sarcoma from leiomyosarcoma
    Ben Davidson
    Department of Pathology, Norwegian Radium Hospital, Oslo University Hospital, N 0424 Oslo, Norway
    Gynecol Oncol 128:349-55. 2013
  2. ncbi Migfilin, α-parvin and β-parvin are differentially expressed in ovarian serous carcinoma effusions, primary tumors and solid metastases
    Ben Davidson
    Division of Pathology, Oslo University Hospital, Norwegian Radium Hospital, N 0424 Oslo, Norway
    Gynecol Oncol 128:364-70. 2013
  3. ncbi The diagnostic and research applications of flow cytometry in cytopathology
    Ben Davidson
    Faculty of Medicine, University of Oslo, N 0316 Oslo, Norway
    Diagn Cytopathol 40:525-35. 2012
  4. ncbi Gene expression signatures differentiate adenocarcinoma of lung and breast origin in effusions
    Ben Davidson
    Division of Pathology, Norwegian Radium Hospital, Oslo University Hospital, N 0310 Oslo, Norway
    Hum Pathol 43:684-94. 2012
  5. ncbi Endoglin (CD105) expression in ovarian serous carcinoma effusions is related to chemotherapy status
    Annika J Bock
    Department of Pathology, Oslo University Hospital, Norwegian Radium Hospital, 0424 Oslo, Norway
    Tumour Biol 32:589-96. 2011
  6. ncbi Osteopontin expression in ovarian carcinoma effusions is related to improved clinical outcome
    Ben Davidson
    Department of Pathology, Oslo University Hospital, Norwegian Radium Hospital, N 0424 Oslo, Norway
    Hum Pathol 42:991-7. 2011
  7. ncbi New determinates of disease progression and outcome in metastatic ovarian carcinoma
    Ben Davidson
    Division of Pathology, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway
    Histol Histopathol 25:1591-609. 2010
  8. ncbi Gene expression signatures differentiate ovarian/peritoneal serous carcinoma from breast carcinoma in effusions
    Ben Davidson
    Division of Pathology, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway
    J Cell Mol Med 15:535-44. 2011
  9. ncbi CD105 (Endoglin) expression in breast carcinoma effusions is a marker of poor survival
    Ben Davidson
    Division of Pathology, Norwegian Radium Hospital, Oslo University Hospital, N 0310 Oslo, Norway
    Breast 19:493-8. 2010
  10. ncbi The diagnostic and molecular characteristics of malignant mesothelioma and ovarian/peritoneal serous carcinoma
    B Davidson
    Division of Pathology, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway
    Cytopathology 22:5-21. 2011

Collaborators

Detail Information

Publications91

  1. ncbi Gene expression signatures differentiate uterine endometrial stromal sarcoma from leiomyosarcoma
    Ben Davidson
    Department of Pathology, Norwegian Radium Hospital, Oslo University Hospital, N 0424 Oslo, Norway
    Gynecol Oncol 128:349-55. 2013
    ..Endometrial stromal sarcoma (ESS) and leiomyosarcoma (LMS) are the two most common uterine sarcomas, but both are rare tumors. The aim of the present study was to compare the global gene expression patterns of ESS and LMS...
  2. ncbi Migfilin, α-parvin and β-parvin are differentially expressed in ovarian serous carcinoma effusions, primary tumors and solid metastases
    Ben Davidson
    Division of Pathology, Oslo University Hospital, Norwegian Radium Hospital, N 0424 Oslo, Norway
    Gynecol Oncol 128:364-70. 2013
    ..The objective of this study is to analyze the expression and clinical role of integrin-linked kinase (ILK), α-parvin, β-parvin and migfilin in advanced-stage serous ovarian carcinoma...
  3. ncbi The diagnostic and research applications of flow cytometry in cytopathology
    Ben Davidson
    Faculty of Medicine, University of Oslo, N 0316 Oslo, Norway
    Diagn Cytopathol 40:525-35. 2012
    ..This article reviews the currently available data in this area of cytopathology...
  4. ncbi Gene expression signatures differentiate adenocarcinoma of lung and breast origin in effusions
    Ben Davidson
    Division of Pathology, Norwegian Radium Hospital, Oslo University Hospital, N 0310 Oslo, Norway
    Hum Pathol 43:684-94. 2012
    ..The molecular signatures unique to these cancers may facilitate their differential diagnosis and may provide a molecular basis for therapeutic target discovery...
  5. ncbi Endoglin (CD105) expression in ovarian serous carcinoma effusions is related to chemotherapy status
    Annika J Bock
    Department of Pathology, Oslo University Hospital, Norwegian Radium Hospital, 0424 Oslo, Norway
    Tumour Biol 32:589-96. 2011
    ..Together with its upregulation in solid metastases, this suggests that the expression and biological role of endoglin may differ between cell populations and change along tumor progression in ovarian carcinoma...
  6. ncbi Osteopontin expression in ovarian carcinoma effusions is related to improved clinical outcome
    Ben Davidson
    Department of Pathology, Oslo University Hospital, Norwegian Radium Hospital, N 0424 Oslo, Norway
    Hum Pathol 42:991-7. 2011
    ..However, its presence in tumor cells at this anatomical site is unexpectedly associated with less aggressive clinical course, suggesting different and yet undefined biological roles for this protein in serous effusions...
  7. ncbi New determinates of disease progression and outcome in metastatic ovarian carcinoma
    Ben Davidson
    Division of Pathology, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway
    Histol Histopathol 25:1591-609. 2010
    ..This review discusses our recent observations with respect to the biology of ovarian carcinoma cells in effusions, and focuses on the clinical role of tumor-associated molecules at this anatomic site...
  8. ncbi Gene expression signatures differentiate ovarian/peritoneal serous carcinoma from breast carcinoma in effusions
    Ben Davidson
    Division of Pathology, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway
    J Cell Mol Med 15:535-44. 2011
    ..The molecular signatures unique to these cancers may facilitate their differential diagnosis and may provide a molecular basis for therapeutic target discovery...
  9. ncbi CD105 (Endoglin) expression in breast carcinoma effusions is a marker of poor survival
    Ben Davidson
    Division of Pathology, Norwegian Radium Hospital, Oslo University Hospital, N 0310 Oslo, Norway
    Breast 19:493-8. 2010
    ..001 and p = 0.038, respectively). Our data suggest that endoglin may be an important therapeutic target in metastatic breast cancer...
  10. ncbi The diagnostic and molecular characteristics of malignant mesothelioma and ovarian/peritoneal serous carcinoma
    B Davidson
    Division of Pathology, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway
    Cytopathology 22:5-21. 2011
    ..This review will present current data regarding the diagnostic and biological aspects of malignant mesothelioma and ovarian/peritoneal serous carcinoma...
  11. ncbi Ovarian carcinoma cells in serous effusions show altered MMP-2 and TIMP-2 mRNA levels
    B Davidson
    Department of Pathology, The Norwegian Radium Hospital, Montebello N 0310, Oslo, Norway
    Eur J Cancer 37:2040-9. 2001
    ..MMP-1 and MMP-2 production predominates over that of MMP-9 in effusions. Increased MMP-2 and reduced TIMP-2 levels are seen in ovarian carcinoma cells in effusions, possibly marking the acquisition of a metastatic phenotype...
  12. ncbi Ets-1 messenger RNA expression is a novel marker of poor survival in ovarian carcinoma
    B Davidson
    Department of Pathology, The Norwegian Radium Hospital, Oslo
    Clin Cancer Res 7:551-7. 2001
    ....
  13. ncbi Expression of cell cycle proteins in ovarian carcinoma cells in serous effusions-biological and prognostic implications
    B Davidson
    Department of Pathology, The Norwegian Radium Hospital, Oslo, Norway
    Gynecol Oncol 83:249-56. 2001
    ..The aim of this study was to investigate the expression of cell cycle proteins in ovarian carcinoma cells in serous effusions and respective solid tumors...
  14. ncbi High levels of MMP-2, MMP-9, MT1-MMP and TIMP-2 mRNA correlate with poor survival in ovarian carcinoma
    B Davidson
    Department of Pathology, The Norwegian Radium Hospital, Montebello, Oslo, Norway
    Clin Exp Metastasis 17:799-808. 1999
    ..006) and MMP-9 levels in tumor cells (P = 0.011) retained their predictive value. We conclude that MMP-2, MMP-9, MT1-MMP and TIMP-2 are valid markers of poor survival in advanced-stage ovarian carcinoma...
  15. ncbi E-cadherin and alpha-, beta-, and gamma-catenin protein expression is up-regulated in ovarian carcinoma cells in serous effusions
    B Davidson
    Department of Pathology, The Norwegian Radium Hospital, Oslo, Norway
    J Pathol 192:460-9. 2000
    ..The up-regulation of E-cadherin complex proteins in serous effusions and metastatic lesions may mark an early metastatic phenotype and possibly mediates survival of tumour cells at these sites through the inhibition of apoptosis...
  16. ncbi Carbohydrate antigen expression in primary tumors, metastatic lesions, and serous effusions from patients diagnosed with epithelial ovarian carcinoma: evidence of up-regulated Tn and Sialyl Tn antigen expression in effusions
    B Davidson
    Department of Pathology, The Norwegian Radium Hospital, Oslo
    Hum Pathol 31:1081-7. 2000
    ..Ovarian carcinoma cells in effusions show up-regulation of Tn and Sialyl Tn, possibly representing a transient phenotypic alteration facilitating metastasis...
  17. ncbi Expression of carbohydrate antigens in advanced-stage ovarian carcinomas and their metastases-A clinicopathologic study
    B Davidson
    Department of Pathology, The Norwegian Radium Hospital, Oslo, Norway
    Gynecol Oncol 77:35-43. 2000
    ....
  18. ncbi Ets-1 mRNA expression in effusions of serous ovarian carcinoma patients is a marker of poor outcome
    B Davidson
    Department of Pathology, The Norwegian Radium Hospital, Oslo, Norway
    Am J Surg Pathol 25:1493-500. 2001
    ..The identical phenotype of carcinoma cells in pleural and peritoneal effusions provides further evidence for our theory that cells at these sites share similar genotypic and phenotypic profiles...
  19. ncbi E-Cadherin complex protein expression and survival in ovarian carcinoma
    B Davidson
    Department of Pathology, The Norwegian Radium Hospital, Montebello, Oslo, N 0310, Norway
    Gynecol Oncol 79:362-71. 2000
    ..The aim of this study was to analyze the correlation between expression of E-cadherin complex proteins, epidermal growth factor receptor (EGFR), and c-erbB-2 and disease outcome in advanced-stage ovarian carcinomas...
  20. ncbi Detection of monocyte/macrophage cell populations in effusions: a comparative study using flow cytometric immunophenotyping and immunocytochemistry
    B Risberg
    Division of Cytology, Department of Pathology, Norwegian Radium Hospital, Oslo, Norway
    Diagn Cytopathol 25:214-9. 2001
    ..Both FCM and ICC aid in the recognition of these cells, and thus provide an effective tool for the identification of different cell populations in effusions...
  21. ncbi Flow cytometric immunophenotyping of serous effusions and peritoneal washings: comparison with immunocytochemistry and morphological findings
    B Risberg
    Department of Pathology, Norwegian Radium Hospital, University of Oslo, Norway
    J Clin Pathol 53:513-7. 2000
    ..To evaluate immunophenotyping by means of flow cytometry as a complementary method for the detection of malignant cells in serous effusions and peritoneal washings...
  22. ncbi PINCH-2 expression in cancers involving serosal effusions using quantitative PCR
    Y Yuan
    Division of Pathology, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway
    Cytopathology 22:22-9. 2011
    ..The objective of the present study was to validate this finding at the mRNA and protein level...
  23. ncbi Flow cytometric measurement of cellular FLICE-inhibitory protein (c-FLIP) in ovarian carcinoma effusions
    H P Dong
    Division of Pathology, Oslo University Hospital, Norwegian Radium Hospital, Oslo, Norway
    Cytopathology 22:373-82. 2011
    ..In addition, we studied the clinical relevance in ovarian carcinoma effusions of this inhibitor protein in the death receptor signalling pathway of apoptosis...
  24. ncbi Differential expression of CD44s and CD44v3-10 in adenocarcinoma cells and reactive mesothelial cells in effusions
    H S Berner
    Department of Pathology, The Norwegian Radium Hospital, University of Oslo, Montebello
    Virchows Arch 436:330-5. 2000
    ..We advocate the use of CD44s and CD44v3-10 immunostaining in diagnostic evaluation of difficult serous effusions...
  25. ncbi Expression of CD44 in effusions of patients diagnosed with serous ovarian carcinoma--diagnostic and prognostic implications
    H S Berner
    Department of Pathology, The Norwegian Radium Hospital, University of Oslo, Montebello
    Clin Exp Metastasis 18:197-202. 2000
    ..The similar expression profile of CD44 in carcinoma cells in peritoneal and pleural effusions supports our previous observations and the hypothesis that carcinoma cells in peritoneal effusions are truly metastatic...
  26. ncbi Detection of cancer cells in effusions from patients diagnosed with gynaecological malignancies. Evaluation of five epithelial markers
    B Davidson
    Department of Pathology, The Norwegian Radium Hospital, Oslo
    Virchows Arch 435:43-9. 1999
    ..Analysis of all staining results should be based on a thorough morphological examination...
  27. ncbi Caveolin-1 expression in advanced-stage ovarian carcinoma--a clinicopathologic study
    B Davidson
    Department of Pathology, The Norwegian Radium Hospital, Montebello, Oslo N 0310, Norway
    Gynecol Oncol 81:166-71. 2001
    ..The aim of this study was to analyze the correlation among the expression of caveolin-1, the protein constituent of caveolae, and disease outcome in advanced-stage ovarian carcinomas...
  28. ncbi Expression of membrane-type 1, 2, and 3 matrix metalloproteinases messenger RNA in ovarian carcinoma cells in serous effusions
    B Davidson
    Dept of Pathology, The Norwegian Radium Hospital, Montebello N-0310, Oslo, Norway
    Am J Clin Pathol 115:517-24. 2001
    ..Tumor cell MT1-MMP expression in effusion specimens did not differ from primary or metastatic lesions. MT-MMP expression in tumor cells in effusions showed no association with effusion site or tumor type using ISH and RT-PCR...
  29. ncbi Measurement of apoptosis in cytological specimens by flow cytometry: comparison of Annexin V, caspase cleavage and dUTP incorporation assays
    H P Dong
    Division of Pathology, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway
    Cytopathology 22:365-72. 2011
    ..To compare the performance of different assays for measuring apoptosis in cytological specimens...
  30. ncbi The diagnostic role of claudins in serous effusions
    Lilach Kleinberg
    Pathology Clinic, Rikshospitalet Radiumhospitalet Medical Center, University of Oslo, Oslo, Norway
    Am J Clin Pathol 127:928-37. 2007
    ..Claudins may, therefore, be of diagnostic value in effusion cytology...
  31. ncbi Ovarian carcinoma and serous effusions. Changing views regarding tumor progression and review of current literature
    B Davidson
    Department of Pathology, The Norwegian Radium Hospital University of Oslo, Montebello, N 0310 Oslo, Norway
    Anal Cell Pathol 23:107-28. 2001
    ..Finally, the prognostic role of these molecules was studied in solid tumors from a patient cohort consisting of long- and short-term survivors, followed for up to 20 years. Figure 1 on http://www.esacp.org/acp/2001/23-3,4/davidson.htm...
  32. ncbi Expression of the folate receptor genes FOLR1 and FOLR3 differentiates ovarian carcinoma from breast carcinoma and malignant mesothelioma in serous effusions
    Yuan Yuan
    National Resource Center for Women s Health, Rikshospitalet University Hospital, Oslo, Norway
    Hum Pathol 40:1453-60. 2009
    ..The high expression of folate receptors in ovarian carcinoma supports their validity as molecular therapeutic targets in this disease...
  33. ncbi The role of desmin and N-cadherin in effusion cytology: a comparative study using established markers of mesothelial and epithelial cells
    B Davidson
    Department of Pathology Division of Cytology, Norwegian Radium Hospital, Oslo, Norway
    Am J Surg Pathol 25:1405-12. 2001
    ..As has previously been shown, a significant number of diagnoses that are based on morphologic examination alone are modified after the use of a broad antibody panel...
  34. ncbi Diagnosis and treatment of borderline ovarian neoplasms "the state of the art"
    C Trope
    Department of Gynaecologic Oncology, The Norwegian Radium Hospital Rikshospitalet Oslo University Hospital, Oslo, Norway
    Eur J Gynaecol Oncol 30:471-82. 2009
    ..been over-treated and how should these patients be treated? How to define the high-risk patients? In which group of patients is fertility-sparing surgery advisable and, do patients with borderline tumours benefit from adjuvant treatment?..
  35. ncbi Kallikrein 4 is expressed in malignant mesothelioma--further evidence for the histogenetic link between mesothelial and epithelial cells
    Ben Davidson
    Pathology Clinic, Rikshospitalet Radiumhospitalet Medical Center, Montebello, N 0310 Oslo, Norway
    Diagn Cytopathol 35:80-4. 2007
    ..The presence of hK4 in MM, a non-hormonally regulated tumor, provides further support to the histogenetic link between mesothelial and epithelial cells...
  36. ncbi Tenascin-X is a novel diagnostic marker of malignant mesothelioma
    Yuan Yuan
    Department of Pathology, Norwegian Radium Hospital, Norway
    Am J Surg Pathol 33:1673-82. 2009
    ....
  37. ncbi Expression of HLA-G in malignant mesothelioma and clinically aggressive breast carcinoma
    Lilach Kleinberg
    Department of Pathology, Norwegian Radium Hospital, University of Oslo, Montebello, 0310 Oslo, Norway
    Virchows Arch 449:31-9. 2006
    ..However, the up-regulated expression of HLA-G in MM effusions and its possible association with shorter disease-free survival in advanced stage of breast carcinoma suggest a possible role in immune response evasion in some tumors...
  38. ncbi Diagnostic and prognostic role of the insulin growth factor pathway members insulin-like growth factor-II and insulin-like growth factor binding protein-3 in serous effusions
    Ana Slipicevic
    Division of Pathology, Norwegian Radium Hospital, Rikshospitalet Medical Center, N 0310 Oslo, Norway
    Hum Pathol 40:527-37. 2009
    ..Insulin-like growth factor-II and insulin-like growth factor binding protein-3 may be novel prognostic markers in metastatic ovarian carcinoma...
  39. ncbi New diagnostic and molecular characteristics of malignant mesothelioma
    Ben Davidson
    Division of Pathology, Norwegian Radium Hospital, Rikshospitalet University Hospital, Oslo, Norway
    Ultrastruct Pathol 32:227-40. 2008
    ..This review presents current data regarding the diagnostic and biological aspects of malignant mesothelioma...
  40. ncbi EMMPRIN (extracellular matrix metalloproteinase inducer) is a novel marker of poor outcome in serous ovarian carcinoma
    Ben Davidson
    Department of Pathology, The Norwegian Radium Hospital, University of Oslo, Oslo, Norway
    Clin Exp Metastasis 20:161-9. 2003
    ..The identical phenotype of carcinoma cells in pleural and peritoneal effusions provides further evidence to our theory that cells at these sites share similar genotypic and phenotypic profiles...
  41. ncbi Different clinical roles for p21-activated kinase-1 in primary and recurrent ovarian carcinoma
    Ben Davidson
    Department of Pathology, Norwegian Radium Hospital, Rikshospitalet University Hospital, Montebello, Oslo, Norway
    Hum Pathol 39:1630-6. 2008
    ..This suggests altered cellular function for this kinase along disease progression, possibly chemotherapy mediated...
  42. ncbi Expression levels of the nerve growth factor receptors TrkA and p75 in effusions and solid tumors of serous ovarian carcinoma patients
    B Davidson
    Department of Pathology, The Norwegian Radium Hospital, Montebello N 0310 Oslo, Norway
    Clin Cancer Res 7:3457-64. 2001
    ....
  43. ncbi Expression and clinical role of antiapoptotic proteins of the bag, heat shock, and Bcl-2 families in effusions, primary tumors, and solid metastases in ovarian carcinoma
    Mari Bunkholt Elstrand
    Section for Gynecologic Oncology, Division of Obstetrics and Gynecology, Norwegian Radium Hospital, Oslo, Norway
    Int J Gynecol Pathol 28:211-21. 2009
    ..HSP70 expression in effusions may be a prognostic marker of poor survival, with a similar role for Bcl-2 in primary carcinomas...
  44. ncbi Evaluation of cell surface expression of phosphatidylserine in ovarian carcinoma effusions using the annexin-V/7-AAD assay: clinical relevance and comparison with other apoptosis parameters
    Hiep Phuc Dong
    Division of Pathology, Norwegian Radium Hospital, Rikshospitalet University Hospital, Montebello N 0310 Oslo, Norway
    Am J Clin Pathol 132:756-62. 2009
    ..The higher annexin-V expression compared with other apoptosis parameters and its association with high-grade disease and poor survival in postchemotherapy patients suggest a role in cell survival rather than apoptosis in effusions...
  45. ncbi Survivin, a member of the inhibitors of apoptosis family, is down-regulated in breast carcinoma effusions
    Lilach Kleinberg
    The Pathology Clinic, Rikshospitalet Radiumhospitalet Medical Center, Oslo, Norway
    Am J Clin Pathol 128:389-97. 2007
    ..Survivin expression may predict disease-free survival for patients with postchemotherapy effusions...
  46. ncbi Expression of the peroxisome proliferator-activated receptors-alpha, -beta, and -gamma in ovarian carcinoma effusions is associated with poor chemoresponse and shorter survival
    Ben Davidson
    Division of Pathology, Norwegian Radium Hospital, Rikshospitalet Medical Center, Montebello N 0310, Oslo, Norway
    Hum Pathol 40:705-13. 2009
    ..Peroxisome proliferator-activated receptor expression in effusions is associated with poor response to chemotherapy at disease recurrence and poor survival, suggesting a role in tumor biology at this unique microenvironment...
  47. ncbi The chemokine receptor CXCR4 is more frequently expressed in breast compared to other metastatic adenocarcinomas in effusions
    Ben Davidson
    Pathology Clinic, Rikshospitalet Medical Center, Montebello, Oslo, Norway
    Breast J 14:476-82. 2008
    ..The prognostic role of CCR7 expression in monocytes and CD8 counts in breast carcinoma effusions merits further research...
  48. ncbi Cadherin expression in ovarian carcinoma and malignant mesothelioma cell effusions
    Stine Sivertsen
    Department of Pathology, National Hospital-Norwegian Radium Hospital, University of Oslo, Oslo, Norway
    Acta Cytol 50:603-7. 2006
    ..05). CONCLUSION: MM and OC/PPC coexpress different cadherin family members. P-cadherin, E-cadherin and N-cadherin are not useful for differentiation between OC/PPC and MM in effusions...
  49. ncbi Caveolin-1 expression in ovarian carcinoma is MDR1 independent
    Ben Davidson
    Department of Pathology, Norwegian Radium Hospital, Oslo
    Am J Clin Pathol 117:225-34. 2002
    ..Expression seems MDR1 independent...
  50. ncbi Kallikrein 4 expression is up-regulated in epithelial ovarian carcinoma cells in effusions
    Ben Davidson
    Department of Pathology, The Norwegian Radium Hospital, Oslo, Norway
    Am J Clin Pathol 123:360-8. 2005
    ..hK4 expression in carcinoma cells of effusions or solid tumors does not predict survival...
  51. ncbi Quantitative analysis of integrin expression in effusions using flow cytometric immunophenotyping
    Eva Sigstad
    Department of Pathology (Section of Cytology, The Norwegian Radium Hospital, Oslo, Norway
    Diagn Cytopathol 33:325-31. 2005
    ..The frequent expression of the alphaV and beta1 subunits support attachment to fibronectin and vitronectin as the major ECM ligands in body cavities...
  52. ncbi NK- and B-cell infiltration correlates with worse outcome in metastatic ovarian carcinoma
    Hiep Phuc Dong
    Department of Pathology, Norwegian Radium Hospital, University of Oslo, Norway
    Am J Clin Pathol 125:451-8. 2006
    ..Immune response parameters in ovarian cancer effusions are weak predictors of outcome...
  53. ncbi The clinical role of phospholipase A2 isoforms in advanced-stage ovarian carcinoma
    Michal Gorovetz
    Department of Pharmacology and Experimental Therapeutics, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Israel, and Department of Gynecologic Oncology, National Hospital-Norwegian Radium Hospital, Oslo, Norway
    Gynecol Oncol 103:831-40. 2006
    ..PLA2 isoenzyme expression differs in pre- and post-chemotherapy specimens. PLAP and sPLA2-XII may be independent predictors of poor outcome for patients with post-chemotherapy effusions...
  54. ncbi Mammalian target of rapamycin is a biomarker of poor survival in metastatic serous ovarian carcinoma
    Mari Bunkholt Elstrand
    Division of Obstetrics and Gynecology, Section for Gynecologic Oncology, Norwegian Radium Hospital, Oslo University Hospital, N 0310 Oslo, Norway
    Hum Pathol 41:794-804. 2010
    ....
  55. ncbi Low-molecular weight forms of cyclin E differentiate ovarian carcinoma from cells of mesothelial origin and are associated with poor survival in ovarian carcinoma
    Ben Davidson
    Pathology Clinic, Radiumhospitalet Rikshospitalet Medical Center, Oslo, Norway
    Cancer 110:1264-71. 2007
    ..In the current study, they analyzed the expression of low-molecular weight (LMW) forms of cyclin E in ovarian carcinoma, malignant mesothelioma, and benign reactive effusions...
  56. ncbi The biological differences between ovarian serous carcinoma and diffuse peritoneal malignant mesothelioma
    Ben Davidson
    Department of Pathology, Norwegian Radium Hospital National Hospital, University of Oslo, Oslo, Norway
    Semin Diagn Pathol 23:35-43. 2006
    ....
  57. ncbi Cleaved caspase-3 and nuclear factor-kappaB p65 are prognostic factors in metastatic serous ovarian carcinoma
    Lilach Kleinberg
    Norwegian Radium Hospital, Rikshospitalet Medical Center, Oslo, Norway
    Hum Pathol 40:795-806. 2009
    ..Nuclear factor-kappaB p65 is frequently expressed in advanced-stage serous ovarian carcinoma, and its nuclear localization is associated with poor progression-free survival...
  58. ncbi Detection of malignant epithelial cells in effusions using flow cytometric immunophenotyping: an analysis of 92 cases
    Ben Davidson
    Department of Pathology, Division of Cytology, Norwegian Radium Hospital, Oslo
    Am J Clin Pathol 118:85-92. 2002
    ..By using established cellular markers coupled with biological markers, FCM also has great promise for experimental purposes...
  59. ncbi Altered expression and activation of the nerve growth factor receptors TrkA and p75 provide the first evidence of tumor progression to effusion in breast carcinoma
    Ben Davidson
    Department of Pathology, The Norwegian Radium Hospital, University of Oslo, Montebello, Oslo, Norway
    Breast Cancer Res Treat 83:119-28. 2004
    ..Furthermore, the rapid progression to effusion in cases showing NGF expression in tumor cells underscores the aggressive clinical behavior of tumors that are able to utilize this pathway in an autocrine manner...
  60. ncbi Flow cytometric immunphenotyping of epithelial cancer cells in effusions--technical considerations and pitfalls
    Hiep P Dong
    Pathology Clinic, Radiumhospitalet Rikshospitalet Medical Center, University of Oslo, Montebello, N 0310 Oslo, Norway
    Cytometry B Clin Cytom 72:332-43. 2007
    ..In the present study, we optimized the conditions for FCM immunphenotyping of effusions using a four-color analysis and investigated aspects related to the advantages and limitations of this method in this setting...
  61. ncbi Expression and clinical role of DJ-1, a negative regulator of PTEN, in ovarian carcinoma
    Ben Davidson
    Pathology Clinic, Rikshospitalet Radiumhospitalet Medical Center, Montebello, N 0310 Oslo, Norway
    Hum Pathol 39:87-95. 2008
    ..In contrast, PTEN expression is infrequent in this disease. These findings may provide one of the molecular mechanisms that mediate cancer cell survival and aggressiveness in this tumor...
  62. ncbi Chemokine receptors are infrequently expressed in malignant and benign mesothelial cells
    Ben Davidson
    Pathology Clinic, Rikshospitalet Radiumhospitalet Medical Center, University of Oslo, Oslo, Norway
    Am J Clin Pathol 127:752-9. 2007
    ..The increased monocyte infiltration and their higher chemokine receptor expression in MM effusions may have a tumor-promoting rather than tumor-inhibiting effect...
  63. ncbi PEA3 is the second Ets family transcription factor involved in tumor progression in ovarian carcinoma
    Ben Davidson
    Department of Pathology, The Norwegian Radium Hospital, Montebello, N 0310 Oslo, University of Oslo, Norway
    Clin Cancer Res 9:1412-9. 2003
    ..The purpose of this study was to analyze the possible correlation between PEA3 mRNA expression and survival in advanced-stage ovarian carcinomas, studying two patient groups with extremely different disease outcome...
  64. ncbi Death receptor expression is associated with poor response to chemotherapy and shorter survival in metastatic ovarian carcinoma
    Hiep Phuc Dong
    Pathology Clinic, Rikshospitalet Radiumhospitalet Medical Center, Oslo, Norway
    Cancer 112:84-93. 2008
    ..Death receptors mediate both apoptosis and survival in cancer cells. The authors analyzed death receptor expression in metastatic ovarian carcinoma...
  65. ncbi Adenomatous polyposis coli (APC) protein expression in primary and metastatic serous ovarian carcinoma
    Eleonora Karbova
    Department of Pathology, The Norwegian Radium Hospital, University of Oslo, Oslo, Norway
    Int J Surg Pathol 10:175-80. 2002
    ..The mechanism behind the down-regulated expression of APC in serous ovarian carcinoma and its significance has yet to be elucidated...
  66. ncbi Different expression and clinical role of S100A4 in serous ovarian carcinoma at different anatomic sites
    Gunhild M Maelandsmo
    Department of Tumor Biology and Surgery, Norwegian Radium Hospital, Rikshospitalet University Hospital, Oslo, Norway
    Tumour Biol 30:15-25. 2009
    ....
  67. ncbi Gross genomic alterations differ between serous borderline tumors and serous adenocarcinomas--an image cytometric DNA ploidy analysis of 307 cases with histogenetic implications
    Manohar Pradhan
    Division of Pathology, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway
    Virchows Arch 454:677-83. 2009
    ....
  68. ncbi Ovarian carcinoma cells in effusions show increased S-phase fraction compared to corresponding primary tumors
    Lilach Kleinberg
    Division of Pathology, The Norwegian Radium Hospital, Rikshospitalet Medical Center, Oslo, Norway
    Diagn Cytopathol 36:637-44. 2008
    ....
  69. ncbi Expression of the chromatin remodeling factor Rsf-1 is down-regulated in breast carcinoma effusions
    Ben Davidson
    Pathology Clinic, Rikshospitalet Radiumhospitalet Medical Center, N 0310 Oslo, Norway
    Hum Pathol 39:616-22. 2008
    ..In conclusion, in contrast to ovarian carcinoma, Rsf-1 expression is down-regulated in breast carcinoma cells in effusions compared with the solid counterparts and has no prognostic role at this anatomic site...
  70. ncbi Expression of activated Akt and PTEN in malignant melanomas: relationship with clinical outcome
    Ana Slipicevic
    Department of Pathology, The Norwegian Radium Hospital, University of Oslo, Oslo, Norway
    Am J Clin Pathol 124:528-36. 2005
    ..025) for patients with superficial spreading melanoma...
  71. ncbi Dissociated expression of Bcl-2 and Ki-67 in endometrial lesions: diagnostic and histogenetic implications
    Björn Risberg
    Department of Pathology, The Norwegian Radium Hospital, Oslo, Norway
    Int J Gynecol Pathol 21:155-60. 2002
    ..The specific finding of inter- and intraglandular Ki-67 heterogeneity may be valuable as an adjunct to morphology in the differential diagnosis of endometrial hyperplasia...
  72. ncbi Activation of c-jun N-terminal kinase is associated with cell proliferation and shorter relapse-free period in superficial spreading malignant melanoma
    Kjersti Jørgensen
    Department of Pathology, The Norwegian Radium Hospital HF, University of Oslo, Oslo, Norway
    Mod Pathol 19:1446-55. 2006
    ..In contrast, activation of p38 seems to play a less important role in development and progression of malignant melanomas...
  73. ncbi Gene expression signatures differentiate ovarian/peritoneal serous carcinoma from diffuse malignant peritoneal mesothelioma
    Ben Davidson
    Department of Pathology, Radiumhospitalet Rikshospitalet Medical Center, University of Oslo, Oslo, Norway
    Clin Cancer Res 12:5944-50. 2006
    ..It remains unclear whether both tumors are molecularly distinct neoplasms. The current study compared global gene expression patterns in OC/PPC and DMPM...
  74. ncbi Growth differentiation factor-15 as a prognostic biomarker in ovarian cancer
    Anne Cathrine Staff
    Department of Gynecology, Oslo University Hospital, Faculty of Medicine, University of Oslo, Oslo, Norway
    Gynecol Oncol 118:237-43. 2010
    ..The aim of the study was to explore preoperative plasma concentration and tissue expression of growth differentiation factor (GDF)-15 in ovarian tumors...
  75. ncbi Expression of inhibitor-of-apoptosis protein family members in malignant mesothelioma
    Lilach Kleinberg
    Pathology Clinic, Rikshospitalet Radiumhospitalet Medical Center, Oslo, Norway
    Hum Pathol 38:986-94. 2007
    ..XIAP is upregulated in mesothelioma effusions and peritoneal mesotheliomas, suggesting a prosurvival role in malignant mesothelioma cells, particularly at these anatomic sites...
  76. ncbi Circulating calprotectin in ovarian carcinomas and borderline tumors of the ovary
    Elin Ødegaard
    Department of Obstetrics and Gynecology, Ulleval University Hospital, Oslo, Norway
    Am J Obstet Gynecol 198:418.e1-7. 2008
    ..Recent studies indicate that circulating calprotectin may serve as a biomarker in some cancers. We investigated whether this is the case for ovarian neoplasms...
  77. ncbi Methods for simultaneous measurement of apoptosis and cell surface phenotype of epithelial cells in effusions by flow cytometry
    Hiep Phuc Dong
    Division of Pathology, Norwegian Radium Hospital, Rikshospitalet Medical Center, Ullernchaussen 70, Montebello, N 0310 Oslo, Norway
    Nat Protoc 3:955-64. 2008
    ..The culturing of cell lines requires 2-3 days and induction of apoptosis requires 16 h...
  78. ncbi The prognostic value of metalloproteinases and angiogenic factors in ovarian carcinoma
    Ben Davidson
    Department of Pathology, The Norwegian Radium Hospital, Montebello 0310, Oslo, Norway
    Mol Cell Endocrinol 187:39-45. 2002
    ..05). We conclude that bFGF is the major angiogenic factor expressed in ovarian carcinoma at the mRNA level. MMP-2, MMP-9, MT1-MMP and TIMP-2 are valid markers of poor survival in advanced-stage ovarian carcinoma...
  79. ncbi Fine-needle aspiration cytology of lobular carcinoma in situ
    Melek Ustün
    Division of Cytology, Department of Pathology, The Norwegian Radium Hospital, University of Oslo, Montebello, N 0310 Oslo, Norway
    Diagn Cytopathol 27:22-6. 2002
    ..However, one should be aware of the cytological features of LCIS in order to reach a correct diagnosis. There are no reliable cytological criteria that help in differentiating pleomorphic and dissociated LCIS from ILC...
  80. ncbi Molecular based treatment of oral cancer
    Jon Sudbø
    Department of Medical Oncology and Radiotherapy, The Norwegian Radium Hospital, Montbello, 0310, Oslo, Norway
    Oral Oncol 39:749-58. 2003
    ..However, the efficiency of any drug for chemopreventive use should be assessed through a prospective randomized trial and evaluated by the only definitive end point for prevention of cancer, the incidence rates of new carcinomas...
  81. ncbi Effusion cytology in ovarian cancer: new molecular methods as aids to diagnosis and prognosis
    Ben Davidson
    Department of Pathology, Norwegian Radium Hospital, University of Oslo, Montebello N 0310 Oslo, Norway
    Clin Lab Med 23:729-54, viii. 2003
    ....
  82. ncbi Expression of the nerve growth factor receptors TrkA and p75 in malignant mesothelioma
    Ben Davidson
    Department of Pathology, The Norwegian Radium Hospital, Montebello N 0310 Oslo, University of Oslo, Oslo, Norway
    Lung Cancer 44:159-65. 2004
    ....
  83. ncbi Kallikrein 4 is associated with paclitaxel resistance in ovarian cancer
    Zhijun Xi
    Department of Biology, University of Oslo, Oslo, Norway
    Gynecol Oncol 94:80-5. 2004
    ..The goal of this study was to investigate if KLK4 protein (hK4) is expressed in ovarian carcinoma lesions and if it is associated with paclitaxel resistance...
  84. ncbi The clinical role of the PEA3 transcription factor in ovarian and breast carcinoma in effusions
    Ben Davidson
    Department of Pathology, The Norwegian Radium Hospital, Montebello, University of Oslo, Oslo, Norway
    Clin Exp Metastasis 21:191-9. 2004
    ..These findings support a biological role for Ets transcription factors in these malignancies and suggests that they may be targets for therapeutic intervention...
  85. ncbi Altered expression of metastasis-associated and regulatory molecules in effusions from breast cancer patients: a novel model for tumor progression
    Ben Davidson
    Department of Pathology, The Norwegian Radium Hospital, Montebello, University of Oslo, Oslo, Norway
    Clin Cancer Res 10:7335-46. 2004
    ....
  86. ncbi Assessment of endoglin and calprotectin as potential biomarkers in ovarian carcinoma and borderline tumors of the ovary
    Elin Ødegaard
    Department of Obstetrics, Ulleval University Hospital, Oslo, Norway
    Am J Obstet Gynecol 199:533.e1-8. 2008
    ..The objective of the study was to analyze circulating endoglin concentration in ovarian carcinoma and evaluate a prognostic role for calprotectin and endoglin in effusions in advanced-stage disease...
  87. ncbi Claudin upregulation in ovarian carcinoma effusions is associated with poor survival
    Lilach Kleinberg
    Pathology Clinic, Rikshospitalet Radiumhospitalet Medical Center, Montebello, N 0310 Oslo, Norway
    Hum Pathol 39:747-57. 2008
    ..Claudin-3 and claudin-7 expression in effusions independently predicts poor survival in OC...
  88. ncbi Heparanase and basic fibroblast growth factor are co-expressed in malignant mesothelioma
    Ben Davidson
    Department of Pathology, The Norwegian Radium Hospital, University of Oslo, Montebello, Oslo, Norway
    Clin Exp Metastasis 21:469-76. 2004
    ....
  89. ncbi Exploring the peritoneal surface malignancy phenotype--a pilot immunohistochemical study of human pseudomyxoma peritonei and derived animal models
    Kjersti Flatmark
    Department of Tumor Biology, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, N 0310 Oslo, Norway
    Hum Pathol 41:1109-19. 2010
    ....
  90. ncbi Genomic aberrations in borderline ovarian tumors
    Francesca Micci
    Section for Cancer Cytogenetics, Institute for Medical Informatics, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway
    J Transl Med 8:21. 2010
    ..According to the scientific literature, less than 30 borderline ovarian tumors have been karyotyped and less than 100 analyzed for genomic imbalances by CGH...
  91. ncbi Nuclear expression of survivin is associated with improved survival in metastatic ovarian carcinoma
    Lilach Kleinberg
    Pathology Clinic, Rikshospitalet Radiumhospitalet Medical Center, Oslo, Norway
    Cancer 109:228-38. 2007
    ..Inhibitor of apoptosis proteins (IAPs) mediate cancer cell survival and chemoresistance. The expression of XIAP, Survivin, and Livin in ovarian carcinoma was analyzed...